IDH2 and glioblastoma: For patients with GBMs, a higher resection rate (P value < 0.05 for both GBM-IDHwt and GBM-IDHm) and treatment with chemotherapy (P value < 0.05 for GBM-IDHwt, and P value = 0.02 for GBM-IDHm) were significantly associated with better prognosis in both the IDH-wildtype and IDH-mutant subgroups.